Cytokinetics beats third quarter 2026 revenue estimates behind $44.5M in MYQORZO sales

Cytokinetics reported third quarter 2026 revenue of $47.6 million, surpassing the $41.2 million estimate as the launch of MYQORZO (aficamten) gained traction. The company recorded a net loss of $1.37 per share, outperforming the projected $1.46 loss while narrowing the year-over-year deficit from $2.55 per share.

Key Highlights

• MYQORZO net product revenue reached $44.5 million, comprised of $43.1 million from the U.S. and $1.4 million from initial sales in Germany.
• Commercial adoption velocity increased with approximately 1,100 unique prescribers and over 2,800 patients dispensed MYQORZO year-to-date as of September 30.
• Liquidity remains strong with $1.6 billion in cash and investments, supporting the planned Supplemental NDA submission for non-obstructive HCM in the fourth quarter 2026.